Objectives There is evidence that inflammation plays a role in the pathogenesis of atherosclerosis. We compared levels of inflammatory markers between patients undergoing carotid endarterectomy (CEA) and controls, and between patients with symptomatic and asymptomatic internal carotid artery (ICA) stenosis.
Materials and Methods A total of 180 patients with ICA stenosis were compared with 180 age-matched and sex-matched controls. The biomarkers evaluated were high-sensitivity C-reactive protein (hs-CRP), soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 (sVCAM-1), and interleukin-6 (IL-6).
Results The levels of hs-CRP, sVCAM-1, and IL-6 in the CEA group were significantly higher than in the control group (1.87 mg/mL vs 1.44 mg/mL, P = .011; 1408 ng/dL vs 672 ng/dL, P < .001; 11.9 pg/mL vs 6.3 pg/mL, P < .001). Multivariate linear regression analysis, adjusted for all clinical and physiologic parameters, showed a significant association between ICA stenosis and hs-CRP, sVCAM-1, and IL-6 concentrations. Analysis of symptomatic (n = 101) and asymptomatic (n = 79) ICA stenosis did not detect a difference in levels of these markers.
Conclusions Our study suggests that inflammatory markers could serve as markers for ICA atherosclerosis but are not useful to identify carotid plaque at risk for symptomatic conversion.
Ross R.Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-126.
2.
Koenig W., Khuseyinova N.Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol. 2007;27:15-26.
3.
Danesh J., Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med . 2004;350:1387-1397.
4.
Boekholdt SM , Hack CE, Sandhu MS, et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis. 2006;187:415-422.
5.
Magliano DJ, Liew D., Ashton EL, Sundararajan V., McNeil JJNovel biomedical risk markers for cardiovascular disease. J Cardiovasc Dis. 2003;10:41-55.
6.
Kaperonis EA , Liapis CD, Kakisis JD, Dimitroulis D., Papavassiliou VGInflammation and atherosclerosis. Eur J Vasc Endovasc Surg. 2006;31:386-393.
7.
Morrone G., Ciliberto G., Oliviero S., et al. Recombinant interleukin-6 regulates the transcriptional activation of a set of human acute phase genes. J Biol Chem. 1988; 263: 12554-12558.
Schillinger M., Exner M., Mlekusch W., et al. Inflammation and carotid artery-risk for atherosclerosis study (ICARAS). Circulation. 2005;111:2203-2209.
10.
Kondo K., Kitagawa K., Nagai Y., Yamagami H., Hashimoto H., Hougaku H.Associations of soluble intercellular adhesion molecule-1 with carotid atherosclerosis progression. Atherosclerosis. 2004;179:155-160.
11.
Baker JD, Rutherford RB, Bernstein EF, Courbier R., Ernst CB, Kempczinski RFSuggested standards for reports dealing with cerebrovascular disease. J Vasc Surg. 1988;8:721-729.
12.
Mocco J., Choudri TF, Mack WJ, et al. Elevation of soluble intercellular adhesion molecule-1 levels in symptomatic and asymptomatic carotid atherosclerosis. Neurosurgery. 2001;48:718-722.
13.
Rerkasem K. , Shearman CP, Williams JA, et al. C-reactive protein is elevated in symptomatic compared with asymptomatic patients with carotid artery disease . Eur J Vasc Endovasc Surg. 2002;23:505-509.
Jager A., van Hinsbergh VW, Kostense PJ, et al. Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes: the HOORN study. Diabetes. 2000;48:183-189.
16.
Clearfield MBC-reactive protein: a new risk assessment tool for cardiovascular disease. J Am Osteopath Assoc. 2005;9:409-416.
17.
Lemieux I., Pascot A., Prud'homme D., et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol . 2001;21:391-397.
18.
Pradhan AD, Manson JE, Rifai N., Buring JE, Ridker PMC-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327-334.
19.
Ridker PM, Rifai N., Pfeffer MA, Sacks F., Braunwald E.Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999;100:230-235.
20.
Larsson PT, Hallerstam S., Rosfors S., Wallen NHCirculating markers of inflammation are related to carotid artery atherosclerosis . Int Angiol. 2005;24:43-51.
21.
De Caterina R., Basta G., Lazzerini G., et al. Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:2646-2654.
22.
Rohde LE, Lee RT, Rivero J., et al. Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 1998;18:1765-1770.
23.
Kondo K., Kitagawa K., Nagai Y., et al. Associations of soluble intercellular adhesion molecule-1 with carotid atherosclerosis progression. Atherosclerosis. 2005;179: 155-160.
24.
Romano M., Mezzetti A., Marulli C., et al. Fluvastatin reduces soluble P-selectin and ICAM-levels in hypercholesterolemic patients: role of nitric oxide. J Invest Med. 2000;48:183-189.
25.
Glass CK, Witztum JLAtherosclerosis, the road ahead. Cell. 2001 ;104:503-516
